tbuckley/cabot-search huggingface dataset:
Evolution of pain in patients with metastatic pancreatic carcinoma treated with FOLFIRINOX or gemcitabine in a randomized phase III study (ACCORD11/PRODIGE4).
Authors: Sophie Gourgou, Marta Jarlier, Antoine Barbieri, Françoise Desseigne, Marc Ychou, Olivier Bouche, Beata Juzyna, Thierry Conroy
Journal: Journal of Clinical Oncology (2015)

e15251 Background: Efficacy of FOLFIRINOX regimen versus Gemcitabine (gem) as first-line therapy among patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) has already been reported (NEJM, 2011; 364:1817-25). An analysis of EORTC Quality of Life (QoL) Questionnaire QLQ-C30 based on a time to definitive deterioration approach (TUDD) confirmed that FOLFIRINOX significantly reduces QoL impairment compared with gem in patients with mPAC. The present exploratory analysis aims to provide some additional insight about the impact of FOLFIRINOX on pain evolution. Methods: Baseline pain scores measured withQLQ-C30 were available for a total of 333/342 pts from the ACCORD11/PRODIGE4 trial (167 and 166 pts in FOLFIRINOX groupand Gem group respectively). The considered endpoint was pain intensity as perceived by the pt according to QLQ-C30 scale and the analgesic consumption at baseline and during treatment. A Linear Mixed Model was used to assess pain score evolution. Results: Baseline QLQ-C30 pain scores were similar between treatment arms (median 33.3 [range, 0-100] and 50 [range, 0-100] for FOLFIRINOXand Gem respectively). Analgesic consumption was also similar both at baseline (26 % of FOLFIRINOX pts vs 34% Gem) and during treatment (73.1% in FOLFIRINOXand 66.9% in Gem). According to the adjusted model, the perceived pain at baseline was significantly higher in the group of pts consuming analgesic with respect to non-consumers (β = 8.05; p = 0.008). The perceived pain tends to decrease significantly across time (β = 0.094; p = 0.0003). Pain intensity perception seems to be lower over time in FOLFIRINOXarm when compared with gem arm (β = -0.034; p = 0.098) adjusted on analgesic consumption. No significant interaction was observed between analgesic consumption and treatment arm over time. Conclusions: During gemcitabine or FOLFIRINOX chemotherapy for mPAC, the perceived pain significantly decrease across time, with a trend to a better control of pain in the FOLFIRINOX group. Clinical trial information: NCT00112658.
Metastatic site location may influence the diagnostic accuracy of plasma EGFR-mutation testing in NSCLC: A pooled analysis
Authors: F. Passiglia, A. Listì, N. Barraco, A. Galvano, D. Fanale, L. Incorvaia, V. Bazan, C. Rolfo, A. Russo
Journal: Annals of Oncology (2017)
A Preliminary Analysis of the Incidence of Transfusion-Related Acute Lung Injury (TRALI) in a Sheep Model Following Transfusion with the Supernatant from Leukodepleted Red Cell Units
Authors: John-Paul Tung, Gabriela Simonova, Sara Diab, Kimble Dunster, Margaret Passmore, Elise Roche, Wesley Bierman, Denisa Meka, Melinda M Dean, John F Fraser
Journal: Blood (2016)
Projected impact and pathways to success of the hepatitis C virus elimination program in Georgia, 2015–2020
Authors: J.G. Walker, L. Hagan, H. Fraser, N.K. Martin, J. Morgan, M. Nasrullah, F. Averhoff, D. Otiashvili, I. Chikovani, M. Aladashvili, M.H. Kuniholm, I. Kirtadze, L. Gvinjilia, A. Asatiani, D. Baliashvili, I. Khonelidze, K. Stvilia, M. Butsashvili, T. Tsertsvadze, A. Gamkrelidze, V. Kvaratskhelia, P. Vickerman
Journal: Journal of Hepatology (2017)
YH25724, a novel long-acting GLP-1/FGF21 dual agonist lowers both non-alcoholic fatty liver disease activity score and fibrosis stage in a diet-induced obese mouse model of biopsy-confirmed non-alcoholic steatohepatitis
Authors: H.N. Hong, J.H. Kim, H.H. Choi, D. Kim, T.W. Kim, K.S. Tølbøl, M. Feigh, M. Illemann, K. Rigbolt, N. Vrang, J.G. Kim
Journal: Journal of Hepatology (2017)
A phase 3 study comparing tenofovir alafenamide to tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: efficacy and safety results at week 96
Authors: M. Brunetto, Y.S. Lim, E. Gane, W.K. Seto, M. Osipenko, S.H. Ahn, H.L. Janssen, A. Shukla, W.L. Chuang, H. Trinh, M.K. Celen, J.F. Flaherty, A.H. Lau, A. Gaggar, V. Suri, N. Bhardwaj, K. Kim, G.M. Subramanian, C. Pan, N. Izumi, P. Marcellin, H. Chan, M. Buti
Journal: Journal of Hepatology (2017)
Association between improved liver function and selenium depends on C718T polymorphism in 3’- untranslated region of glutathione peroxidase 4 and in humans
Authors: N. Rohr-Udilova, S. Theiner, S. Beinhardt, A. Stättermayer, T. Scherzer, M. Seif, G. Köllensperger, B. Keppler, E. Eder, C. Willheim, T. Reiberger, H. Hofer, M. Peck-Radosavljevic, P. Ferenci, M. Trauner
Journal: Journal of Hepatology (2017)
Enhanced Surgical Recovery Through Enhanced Research From Integrated Health Systems
Authors: Mohammed Bayasi, Waddah Al-Refaie
Journal: JAMA Surgery (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Abstract 153: Using the Embryonic Heart as an Instructive Template for Cardiac Tissue Engineering
Authors: Ivan Batalov, Quentin Jallerat, Adam W Feinberg
Journal: Circulation Research (2015)

The engineering of highly aligned cardiomyocytes into functional heart muscle remains a primary challenge in cardiac tissue engineering. Researchers have shown that micropatterned topography and chemistry as well as mechanical and electrical gradients are all effective at inducing some degree of alignment. However, which approach works best in terms of electromechanical function of the engineered cardiac muscle is still an active area of research. Because formation of new heart muscle in mammals primarily occurs during cardiogenesis, we asked whether the embryonic heart could be used as an instructive template for the design of more effective cardiac tissue engineering scaffolds. Specifically, we hypothesized that micropatterns of fibronectin based on fibronectin fibril size and architecture in embryonic myocardium could improve cardiomyocyte alignment relative to 20 μm wide, 20 μm spaced fibronectin lines, a control pattern used widely in the literature. To test this, we first imaged the fibronectin matrix in the ventricles of day-5 embryonic chick hearts and imaged this in 3D using a multiphoton microscope. This fibronectin structure was then converted into a photomask for photolithography and subsequent patterning of fibronectin onto cover slips using microcontact printing. Samples with the biomimetic patterns or control patterns were seeded with embryonic chick cardiomyocytes, cultured for 3 days and then stained and imaged to visualize the myofibrils. Image analysis to quantify alignment showed that the ability of the biomimetic pattern to induce cardiomyocyte alignment increased with cell density, suggesting that cell-cell interactions play an important role in the formation of aligned embryonic myocardium. Disruption of the cadherins junctions using blocking antibodies confirmed this conclusion. In the future we will use human induced pluripotent stem cell-derived cardiomyocytes to engineer more clinically-relevant human heart muscle and analyze electromechanical function of the tissues including contractile force and action potential propagation.
Activation of miR-34a contributes to liver and muscle insulin resistance in experimental and human non-alcoholic fatty liver disease
Authors: A.L. Simão, M.B. Afonso, P.M. Rodrigues, A.J. Amaral, M. Gama-Carvalho, H. Cortez-Pinto, C.M.P. Rodrigues, R.E. Castro
Journal: Journal of Hepatology (2017)
Microrna-138 Regulates Osteogenic Differentiation and Its Inhibition Presents a Novel Therapeutic Line to Prevent Bone Lytic Lesions in Multiple Myeloma
Authors: Shokichi Tsukamoto, Karma Salem, Salomon Manier, Michaela R. Reagan, Daisy Huynh, Adriana Perilla-Glen, Antonio Sacco, Oksana Zavidij, Mahshid Rahmat, Satoshi Takagi, Yawara Kawano, Katsutoshi Kokubun, Charlotte Albæk Thrue, Andreas Petri, David M. Dorfman, Aldo M. Roccaro, Marzia Capelletti, Sakari Kauppinen, Irene M. Ghobrial
Journal: Blood (2016)
Patterns and challenges of treatment sequencing in patients with hepatocellular carcinoma
Authors: M.M. Kirstein, N. Schweitzer, T. Winter, K. Lappas, N. Graen, I. Kunstmann, T. Voigtländer, T. Reineke-Plaaß, M.P. Manns, T. Rodt, F. Lehner, A. Vogel
Journal: Journal of Hepatology (2017)
Optimal timing of discontinuation of clopidogrel and risk of blood transfusion after coronary surgery. Propensity score analysis
Authors: Giovanni Mariscalco, Domenico Bruno, Marzia Cottini, Paolo Borsani, Maciej Banach, Gabriele Piffaretti, Carmelo Dominici, Cesare Beghi, Andrea Sala
Journal: Circulation Research (2011)
In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy
Authors: Sean P. Arlauckas, Christopher S. Garris, Rainer H. Kohler, Maya Kitaoka, Michael F. Cuccarese, Katherine S. Yang, Miles A. Miller, Jonathan C. Carlson, Gordon J. Freeman, Robert M. Anthony, Ralph Weissleder, Mikael J. Pittet
Journal: Science Translational Medicine (2017)

Tumor-associated macrophages limit anti–PD-1 effects by removing the antibody from CD8 + T cells.
Prognostic and clinical impact of sarcopenia in esophageal squamous cell carcinoma.
Authors: Yoshifumi Baba, Kazuto Harada, Satoshi Ida, Junji Kurashige, Yukiharu Hiyoshi, Shiro Iwagami, Yuji Miyamoto, Yasuo Sakamoto, Naoya Yoshida, Masayuki Watanabe, Hideo Baba
Journal: Journal of Clinical Oncology (2015)

e15035 Background: Recently, depletion of skeletal muscle mass (sarcopenia) has been linked to poor prognosis in several types of cancers, but has not been investigated in esophageal squamous cell carcinoma (ESCC). This retrospective study investigates the relationship between sarcopenia and clinical outcome in ESCC patients treated by surgical resection or definitive chemoradiation therapy (dCRT). Methods: The study was conducted in a single academic hospital in Kumamoto, Japan, and involved 325 ESCC patients (256 surgical cases and 69 dCRT cases) treated between 2005 and 2011. Skeletal muscle mass was quantified by radiologic measures using standard computed tomography scans at the first visit. A Cox proportional hazards model was used to calculate the hazard ratio (HR), adjusted for the clinical and pathological variables. The term “prognostic marker” is used throughout this study according to the REMARK Guidelines. Results: Sarcopenia was not significantly associated with overall survival (log rank p = 0.54). Lymph node involvement significantly altered the relationship between sarcopenia and survival rate (p for interaction = 0.026). Sarcopenia significantly reduced the overall survival of patients without lymph node involvement [log rank p = 0.035; HR 1.93; 95% confidential interval (CI) 1.02-3.60], but was uncorrelated with overall survival in patients with lymph involvement (log rank, p = 0.31; HR 0.79; 95% CI 0.50-1.23). Notably, the effect of sarcopenia did not significantly differ between the surgery group and the dCRT gruop (P for interaction = 0.43). The anastomosis leakage rate was significantly higher in the sarcopenia group than in the non-sarcopenia group (p = 0.032), but other surgical complications did not significantly differ between the two groups. Conclusions: Sarcopenia in ESCC patients without lymph node involvement is associated with poor prognosis, indicating sarcopenia as a potential biomarker for identifying patients likely to experience an inferior outcome. Moreover, sarcopenia was associated with anastomosis leakage but no other short-term surgical outcome.
Inhibition of Akt phosphorylation is involved in therapeutic synergy between telomerase-specific replication competent oncolytic adenovirus (Telomelysin) and histone deacetylase inhibitor (AR42) in human hepatocellular carcinoma
Authors: Z.-Z. Lin, C. Hsu, N.-Y. Sun, W.-F. Cheng, S.-H. Yeh, C.-S. Chen, P.-J. Chen, A.-L. Cheng
Journal: Journal of Hepatology (2017)
Noninvasive assessment of liver fibrosis and portal hypertension after viral eradication in post-transplant hepatitis C
Authors: E. Mauro, G. Crespo, M.C. Londoño, A. Diaz, P. Ruiz, L. Sastre, J. Lombardo, J. Aguirre, J. Colmenero, M. Navasa
Journal: Journal of Hepatology (2017)
Distinct immune and regulatory functions of IgG1+ and IgG4+ B cells in IgG4-related disease
Authors: T. Cargill, E.L. Culver, M. Makuch, L.L. Lighaam, W. Smit, E. Vermeulen, R. Aalberse, P. Klenerman, T. Rispens, E. Barnes
Journal: Journal of Hepatology (2017)
Maker of Duodenoscopes Under Scrutiny Again
Authors: Jeff Lyon
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The restoration of a healthy intestinal microbiota by fecal transplantation normalizes portal hypertension and endothelial dysfunction in a rat model of diet-induced non-alcoholic steatohepatitis
Authors: T. García-Lezana, M. Martell, I. Raurell, M. Bravo, M. Torres-Arauz, M.T. Salcedo, C. Manichanh, J. Genescà, S. Augustin
Journal: Journal of Hepatology (2017)
A phase 2a study evaluating the multi-dose activity of ARB-1467 in HBeAg positive and negative virally suppressed subjects with hepatitis B
Authors: A. Streinu-Cercel, E. Gane, W. Cheng, W. Sievert, S. Roberts, S.H. Ahn, Y.J. Kim, K. Agarwal, D. Niforos, B. Symonds, P. Mendez
Journal: Journal of Hepatology (2017)
A randomized, double-blind, clinical trial comparing lactulose, l-ornithine l-aspartate, or rifaximin, versus placebo, as primary prophylaxis of hepatic encephalopathy in cirrhotic patients with variceal bleeding
Authors: F.H. de La Tijera, A.I. Servín-Caamaño, J.M. Abdo-Francis, F. Salas-Gordillo, J.L. Pérez-Hernández, J. Camacho-Aguilera, S.N. Alla, F. Jiménez-Ponce
Journal: Journal of Hepatology (2017)
Tumor Dormancy and Relapse: From a Natural Byproduct of Evolution to a Disease State
Authors: Masoud H. Manjili
Journal: Cancer Research (2017)

Abstract Species evolve by mutations and epigenetic changes acting on individuals in a population; tumors evolve by similar mechanisms at a cellular level in a tissue. This article reviews growing evidence about tumor dormancy and suggests that (i) cellular malignancy is a natural byproduct of evolutionary mechanisms, such as gene mutations and epigenetic modifications, which is manifested in the form of tumor dormancy in healthy individuals as well as in cancer survivors; (ii) cancer metastasis could be an early dissemination event that could occur during malignant dormancy even before primary cancer is clinically detectable; and (iii) chronic inflammation is a key factor in awakening dormant malignant cells at the primary site, leading to primary cancer development, and at distant sites, leading to advanced stage diseases. On the basis of this evidence, it is reasonable to propose that we are all cancer survivors rather than cancer-free individuals because of harboring dormant malignant cells in our organs. A better understanding of local and metastatic tumor dormancy could lead to novel cancer therapeutics for the prevention of cancer. Cancer Res; 77(10); 2564–9. ©2017 AACR.
Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial
Authors: Chongsheng Qian, Arnaud Campidelli, Yingying Wang, Huili Cai, Véronique Venard, Hélène Jeulin, Jean Hugues Dalle, Cécile Pochon, Maud D’aveni, Benedicte Bruno, Catherine Paillard, Stéphane Vigouroux, Charlotte Jubert, Patrice Ceballos, Aude Marie-Cardine, Claire Galambrun, Clément Cholle, Isabelle Clerc Urmes, Nadine Petitpain, Marcelo De Carvalho Bittencourt, Véronique Decot, Loïc Reppel, Alexandra Salmon, Laurence Clement, Danièle Bensoussan
Journal: Journal of Hematology & Oncology (2017)

Allogeneic hematopoietic stem cell transplantation (HSCT), the most widely used potentially curable cellular immunotherapeutic approach in the treatment of hematological malignancies, is limited by life-threatening complications: graft versus host disease (GVHD) and infections especially viral infections refractory to antiviral drugs. Adoptive transfer of virus-specific T cells is becoming an alternative treatment for infections following HSCT. We report here the results of a phase I/II multicenter study which includes a series of adenovirus-specific T cell (ADV-VST) infusion either from the HSCT donor or from a third party haploidentical donor for patients transplanted with umbilical cord blood (UCB). Fourteen patients were eligible and 11 patients received infusions of ADV-VST generated by interferon (IFN)-γ-based immunomagnetic isolation from a leukapheresis from their original donor (42.9%) or a third party haploidentical donor (57.1%). One patient resolved ADV infection before infusion, and ADV-VST could not reach release or infusion criteria for two patients. Two patients received cellular immunotherapy alone without antiviral drugs as a pre-emptive treatment. One patient with adenovirus infection and ten with adenovirus disease were infused with ADV-VST (mean 5.83 ± 8.23 × 103 CD3+IFN-γ+ cells/kg) up to 9 months after transplantation. The 11 patients showed in vivo expansion of specific T cells up to 60 days post-infusion, associated with adenovirus load clearance in ten of the patients (91%). Neither de novo GVHD nor side effects were observed during the first month post-infusion, but GVHD reactivations occurred in three patients, irrespective of the type of leukapheresis donor. For two of these patients, GVHD reactivation was controlled by immunosuppressive treatment. Four patients died during follow-up, one due to refractory ADV disease. Adoptive transfer of rapidly isolated ADV-VST is an effective therapeutic option for achieving in vivo expansion of specific T cells and clearance of viral load, even as a pre-emptive treatment. Our study highlights that third party haploidentical donors are of great interest for ADV-VST generation in the context of UCB transplantation. (N° Clinical trial.gov: NCT02851576, retrospectively registered).
Ledipasvir/sofosbuvir ± ribavirin for 12 or 24 weeks is safe and effective in children 6–11 years old with chronic hepatitis C infection
Authors: K.F. Murray, W. Balistreri, S. Bansal, S. Whitworth, H. Evans, R.P. Gonzalez-Peralta, J. Wen, B. Massetto, K. Kersey, Y. Zhu, K. Garrison, E. Svarovskaia, D.M. Brainard, R. Arnon, L. Gillis, M.M. Jonas, C.-H. Lin, M.R. Narkewicz, K. Schwarz, P. Rosenthal
Journal: Journal of Hepatology (2017)
Survival in patients with chronic hepatitis C and mild-moderate fibrosis according to antiviral treatment response
Authors: M. Puigvehí, S. Coll, A. Raga, A. Soriano, N. Cañete, T. Broquetas, M. García-Retortillo, M. García, J. Gimeno, R. Fernández, B. Cabrero, M.D. Giménez, R. Solà, J.A. Carrión
Journal: Journal of Hepatology (2017)
Long-term follow-up after IFN-free therapy of advanced HCV-associated liver cirrhosis: continued improvement of liver function parameters – Results from the German Hepatitis C-Registry (DHC-R)
Authors: K. Deterding, S. Mauss, A. Pathil, P. Buggisch, E. Schott, M. Cornberg, T. Zimmermann, K.-G. Simon, H. Klinker, R. Günther, H. Pfeiffer-Vornkahl, D. Hueppe, C. Sarrazin, S. Zeuzem, M.P. Manns, H. Wedemeyer, T. Berg
Journal: Journal of Hepatology (2017)
Continued improvement in renal laboratory parameters in CHB patients treated with tenofovir alfenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) over 96 weeks
Authors: W.L. Chuang, K. Agarwal, J.S. Hwang, F. Caruntu, F. Wong, H.W. Hann, J. Flaherty, A. Lau, A. Gaggar, V. Suri, S. Mo, G.M. Subramanian, A.J. Hui, H. Yatsuhashi, Y.S. Lim
Journal: Journal of Hepatology (2017)
Choosing mastectomy over lumpectomy: Factors associated with surgical decisions in young women with breast cancer.
Authors: Shoshana M. Rosenberg, Karen Sepucha, Kathryn Jean Ruddy, Rulla M. Tamimi, Shari I. Gelber, Meghan E Meyer, Lidia Schapira, Steven E. Come, Virginia F. Borges, Eric P. Winer, Ann H. Partridge
Journal: Journal of Clinical Oncology (2013)

6507 Background: Few studies have comprehensively evaluated surgical decisions in young women with breast cancer. Young women have unique medical and psychosocial concerns, and identifying factors associated with surgical choices in this population can inform their decision-making process. Methods: As part of an ongoing multi-center cohort study enrolling women diagnosed with breast cancer at age 40 or younger, we evaluated 277 women with stage I-III disease who indicated they had a choice between mastectomy and breast conserving surgery (BCS). Logistic regression was used to identify predictors of choosing mastectomy vs. BCS. Independent variables with a p-value ≤ 0.15 in bi-variate analyses were included in the final multivariable model. Results: 172/277 women (62%) had either a single or bilateral mastectomy as their definitive surgery. Median age at diagnosis was 37 (range: 17-40). Most women were married (75%), had stage I or II disease (90%), and estrogen receptor (ER) positive tumors (65%); approximately 14% were carriers of a BRCA 1 or 2 mutation. In the multivariable analysis (Table), having a mutation, nodal involvement, HER2-positivity, tumor grade, lower BMI, having 2 or more children, anxiety, and decisional involvement by the patient were all associated with mastectomy. Age, race, marital status, tumor size, having a first degree relative with breast or ovarian cancer, ER status, fear of recurrence, and depression were not significantly associated with having a mastectomy. Conclusions: Despite being candidates for BCS, many young women choose to have a mastectomy. Our results suggest potential targets for interventions such as anxiety reduction and fostering fully informed shared decision-making. [Table: see text]